AlvioLife® (Respiratory Health & Performance)

Spilanthes acmella / Boswellia serrata
Evidence Level
Moderate
1 Clinical Trial
3 Documented Benefits
3/5 Evidence Score

AlvioLife® (PLT Health Solutions) is a patented botanical blend combining Spilanthes acmella (toothache plant) and Boswellia serrata extracts to support respiratory health, easier breathing, and enhanced physical performance. By targeting bronchial airway inflammation and improving respiratory efficiency, AlvioLife® addresses a foundational aspect of endurance performance — oxygen delivery — through a non-stimulant botanical mechanism.

Studied Dose Per AlvioLife® clinical dosing; PLT Health Solutions product specifications
Active Compound Proprietary blend of Spilanthes acmella flower head extract and Boswellia serrata resin extract — AlvioLife® by PLT Health Solutions; standardized for spilanthol and AKBA content

Easier breathing and airway support

AlvioLife® reduces bronchial airway inflammation through Boswellia's AKBA (acetyl-11-keto-β-boswellic acid) inhibition of 5-lipoxygenase — the enzyme producing leukotrienes that trigger bronchoconstriction and airway inflammation. This mechanism is the same target as pharmaceutical leukotriene inhibitors (montelukast) but through a botanical route, supporting freer, less restricted breathing.

Enhanced physical performance and VO2

By improving respiratory efficiency and reducing airway resistance, AlvioLife® allows athletes to draw more oxygen per breath — translating to improved VO2 utilization, greater endurance capacity, and better performance during sustained aerobic exercise. Clinical studies show improvements in respiratory function markers and exercise performance.

Immune and respiratory resilience

Spilanthes acmella provides immunostimulatory alkylamides (spilanthol) that activate macrophages and natural killer cells — enhancing upper respiratory immune defense. The combination of anti-inflammatory Boswellia and immunostimulatory Spilanthes creates a dual protective and active immune profile for respiratory health.

1

5-LOX inhibition and leukotriene reduction

AKBA from Boswellia serrata selectively inhibits 5-lipoxygenase (5-LOX) — the enzyme responsible for converting arachidonic acid to pro-inflammatory leukotrienes (LTB4, LTC4, LTD4). Leukotrienes are the primary mediators of bronchospasm, mucus hypersecretion, and airway inflammation in respiratory conditions. By blocking 5-LOX, AlvioLife® reduces leukotriene-driven airway constriction and inflammation without the COX inhibition side effects of NSAIDs.

1
AlvioLife® Respiratory Function and Exercise Performance — Clinical Study
PubMed

Clinical study examining AlvioLife® effects on respiratory function, breathing comfort, and exercise performance markers.

Adults with respiratory concerns and active individuals. Clinical study design.

AlvioLife® supplementation improved respiratory function markers, reduced airway inflammation indicators, and enhanced exercise performance capacity vs. baseline. Both respiratory health and performance benefits confirmed. Well-tolerated. Full study details available through PLT Health Solutions.

Common Potential side effects

Generally well tolerated
Boswellia component — rare GI effects; take with food
Spilanthes component — mild tingling sensation (spilanthol) is normal

Important Drug interactions

Anticoagulants — Boswellia has mild antiplatelet activity; monitor if on blood thinners
Asthma medications — complementary anti-inflammatory mechanism; not a replacement for prescribed asthma therapy